Request for Information (RFI): Data and Biospecimen Resources for Studying Addiction-Related Rare Genetic Variants in Families

Notice Number: NOT-DA-12-017

Update: The following update relating to this announcement has been issued:

Key Dates
Release Date: August 6, 2012
Response Date:  (Extended to December 31, 2012 per NOT-DA-13-008), Originally September 7, 2012

Issued by
National Institute on Drug Abuse (NIDA)


This Notice is a time-sensitive Request for Information (RFI) soliciting input for strategic planning in human genomics research funded by the National Institute on Drug Abuse (NIDA). The purpose is to invite responses  from the research community about ongoing family studies and pedigree data resources in the U.S. and internationally that could be leveraged for the identification and characterization of rare genetic and pharmacogenetic variants related to addiction phenotypes and co-morbid conditions, in the context of environmental exposures.


NIDA has an established addiction genetics research program that includes a funded grants portfolio in human genomics, pharmacogenomics, and genetic epidemiology (see A 2012 NIH Guide Notice of NIDA’s Priorities for Human Genetics Research communicated funding priorities in the post-genome wide association study period that emphasize targeted, whole-genome or -exome sequencing, and/or bioinformatic and computational approaches, to identify and characterize genetic variants contributing to addiction liability and treatment outcomes. In considering future directions, NIDA wishes to learn about the types of existing or adaptable resources that may be available for large-scale efforts to advance discovery, replication, and characterization of rare variants in multi-generational pedigrees.

 Information Requested

Specific and detailed Information is sought about ongoing studies and data resources with existing or readily obtainable phenotypic data describing addictive substance use and dependence in families.  To be in scope for this Request, sequencing data on probands and a minimum set of relatives should be accessible under NIH data sharing terms, or else DNA should be available or readily obtainable for sequencing. “Readily obtainable” generally refers to availability within a 3-5 year timeline and reasonable budget constraints. De novo studies are not currently under consideration; however, researchers may comment on why existing family-based resources may not be adequate or modifiable to meet research needs. Statements about research gaps in rare variant discovery are also broadly invited, including from investigators not currently leading ongoing family studies or otherwise managing family-based resources. Input is sought on the areas described below, as well as on other related items that the research community might consider. 
Response to this RFI is voluntary.  Responders are free to address any or all of the following items. Please note that the Government will not pay for response preparation or for the use of any information contained in the response.  Responses will be used for program planning at NIDA and this RFI should not be construed as a solicitation or as an obligation on the part of the Federal Government, the National Institutes of Health (NIH), and/or NIDA. Anonymity of respondents cannot be guaranteed.  Existing documentation of studies, databases, variables, study designs can be submitted under this request.

For international studies conducted outside the U.S., describe policies, procedures, consent, or other issues that might have an impact on the sharing of data and DNA with international collaborators.

How to Submit a Response 

Responses to this RFI will be accepted through September 30, 2012 via email to Louise Wideroff, PhD MSPH at  Respondents will receive an electronic confirmation acknowledging receipt of their response, but will not receive individualized feedback on any suggestions.  No basis for claims against the U.S. Government shall arise as a result of a response to this request for information or from the Government’s use of such information.


Specific questions about this RFI should be directed to:

Louise Wideroff, PhD, MSPH
Program Official, Office of the Director
Division of Basic Neuroscience and Behavioral Research
National Institute on Drug Abuse
6001 Executive Boulevard
Rm. 4271, MSC 9555
Bethesda, MD 20892-9555
Tel: 301-451-8663
Fax: 301-594-6043

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy
NIH . . . Turning Discovery Into Health

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.